Sino-Biocan
Latest round
- Series B
Last raised
- Mar 2024
Total raised
- $30M
Investors
- 6
About Sino-Biocan
Based in Beijing, China, and founded in 2013. Sino-Biocan operates as a biotechnology company, focusing on the screening, diagnosis, treatment, and health management of tumors, cardiovascular and cerebrovascular diseases, immune diseases, and geriatric diseases. It has acquired ISO9001 and ISO13485 quality management system certification and cooperated with 86 partners. In November 2021, the cell preparation tool production base was completed. As of 2022, the company has nearly 50 employees. The founder, Dongbing Wei, used to serve as the head of Meitianni. He has experience in equipment and consumables. The company's products can be categorized into automatic cell separation, automatic cell culture, automatic cell washing, and so on. In addition, it also provides users with tumor early screening services such as tumor antigen detection, circulating tumor cells, and DNA detection. Its products are widely used in the fields of cell and genetic drug development, medical stem cell preparation and application, umbilical blood bank management, and cell storage. The business has covered Beijing, Hong Kong, and other places. The company will use the series B funds to build a production system, enhance research and development capabilities and global registration capabilities, and expand the global market.
Who invested in Sino-Biocan
6 investors across 4 rounds
See all investors in Sino-Biocan
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Sino-Biocan
Who invested in Sino-Biocan?
Sino-Biocan has 6 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Sino-Biocan raised?
Sino-Biocan has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Sino-Biocan last raise money?
Sino-Biocan's most recent round on record is a Series B, in Mar 2024.
What does Sino-Biocan do?
Based in Beijing, China, and founded in 2013.
Where is Sino-Biocan headquartered?
Sino-Biocan is headquartered in Shanghai, China.
Which VCs invest in companies like Sino-Biocan?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Sino-Biocan's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Sino-Biocan? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.